Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
After watching this activity, participants should be better able to:
- Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
- Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
- Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis
In this activity, two expert haematologic oncologists respond to questions from the haematology and oncology communities on how to select a first-line JAK inhibitor for patients with myelofibrosis, the key side effects associated with JAK inhibitors and how these are best managed, and review second-line treatment options following first-line JAK inhibitor treatment failure.
This activity is jointly provided by USF Health and touchIME. read more
Haematologists and oncologists (including haematologic oncologists) involved in the management of myelofibrosis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Prof. John Mascarenhas discloses Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Celgene, CTI BioPharma, Galecto Biotech, Geron Corporation, GlaxoSmithKline, Imago BioSciences, Inc., Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Pfizer, PharmaEssentia and Sierra Oncology. Grants/research support from AbbVie, Bristol Myers Squibb, Geron Corporation, Incyte Corporation, Kartos Therapeutics, Novartis and PharmaEssentia.
Dr Raajit Rampal discloses Advisory board or panel fees from AbbVie, Galecto Biotech, GlaxoSmithKline, Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, PharmaEssentia and SDP Pharma. Consultancy fees from Bristol Myers Squibb/Celgene, CTI BioPharma, MorphoSys, Servier, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals. Grants/research support from Constellation Pharmaceuticals, Ryvu Therapeutics, Stemline Therapeutics Inc. and Zentalis Pharmaceuticals.
Amy Patterson, APRN: Speakers Bureau: Gilead/Kite (Relationships Terminated).
Touch Medical Contributors
Katrina Lester and Aniket Parikh have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 31 July 2023. Date credits expire: 31 July 2024.
If you have any questions regarding credit please contact firstname.lastname@example.org.
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinicThis activity is CE/CME accredited
Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practiceThis activity is CE/CME accredited
Anna Sureda, EBMT23: The lastest from the HARMONY Alliance and the Big Data Platform
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 9 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGYSign me up!